Morgan Stanley Maintains Equal-Weight on Organogenesis Hldgs, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri has maintained an Equal-Weight rating on Organogenesis Hldgs (NASDAQ:ORGO) but lowered the price target from $5 to $3.
August 11, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Organogenesis Hldgs but lowered the price target from $5 to $3.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100